Results

Total Results: 1,187 records

Showing results for "weeks".

21. Evidence Report on the (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/preterm-birth-terbutaline-pump_research-protocol.pdf
    October 18, 2010 - gestation), including subgroups of <28 weeks gestation, <32 weeks, <34 weeks and <37 weeks, as well … , <32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birthweight, ratio of birthweight … , < 32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birthweight, ratio of birthweight … gestation KQ2a, KQ2b: < 32 weeks gestation KQ1c, KQ2c: <34 weeks gestation KQ1d, KQ2d: <37 weeks … , <32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy, birthweight, ratio of birthweight

22. Disposition of Comments Report for Comparative Effectiveness Review No. 131 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/crohns-disease_disposition-comments.pdf
    February 25, 2014 - “immediate response”; 8-12 weeks “induction”; 15-19 weeks “4 months”; 18-24 weeks “long-term”; 22-30 … weeks “six months”; 48-54 weeks “1 year”. … at 12-16 weeks. … Those patients who lost response >8 weeks but ≤12 weeks received 5 mg/kg every 8 weeks. … weeks.

23. Supplemental Project To Assess the Transparency of Reporting Requirements for Studies Evaluating the Effectiveness of Treatment Options for Symptoms of Diabetic Peripheral Neuropathy (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/transparency-neuropathy_research.pdf
    March 01, 2018 - Backonja, 199833a Not found NA NA NA 165 8 weeks Simpson, 200134a Not found NA NA NA 60 8 weeks … § 6 weeks None identified NCT00785577 NA Jun 2010 Yes 273 5 weeks None identified NCT01332149 NA … Jun 2014 Yes 626 9 weeks None identified NCT01455415 NA Nov 2013 Yes 306 6 weeks None identified … weeks CT.gov only None identified NCT00231673 NA Jan 2003 No 72 18 weeks a Study was identified … 2 weeks Oskarsson, 199762a Not found NA NA NA 126 3 weeks Wright, 199763a Not found NA NA

24. Infectious Disease Including HIV/AIDS #09 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1412.pdf
    December 22, 2014 - Eight weeks of ledipasvir/sofosbuvir therapy was noninferior to 12 weeks of ledipasvir/sofosbuvir therapy … with HCV genotype 2, for 24 weeks for patients infected with genotype 3, and for 12 weeks with IFN … Eight weeks of ledipasvir/sofosbuvir therapy was noninferior to 12 weeks of ledipasvir/sofosbuvir therapy … Patients treated for 24 weeks had an SVR12 of 96%. … , or sofosbuvir plus weight-based RBV for 24 weeks

25. Infectious Disease Including HIV/AIDS #09 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1512.pdf
    January 28, 2016 - weeks. … , or Sovaldi 400 mg plus RBV for 12 weeks (genotype 2) or 24 weeks (genotype 3). … weeks without RBV. … or Technivie alone for 24 weeks. … RBV for 12 weeks, or Sovaldi plus weight-based RBV for 24 weeks.

26. Carbohydrate-Intake-Prepub-Final-Research-Table-Da (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-prepub-final-research-table-da.xlsx
    January 01, 2019 - vs. moderately higher carbohydrate diet in women with obesity vs. women of normal weight 16 to 20 weeks … Nutrients calculated using a Nutrition Calculator (V2.7.3) Low-carbohydrate diet Between 24 and 28 weeks … ) and endpoint (36-37 weeks) FFQ (self-administered 360-item FFQ covering intakes during the previous … 4 weeks) Age, mean years (SD): 31.2 (4.4) BMI, median kg/m2 (10th-90th percentile): 32.6 (30.3-40.3) … gestation, and 28 weeks gestation 24-hour recalls at the 3 time periods Quintile 1 vs. quintile 2 vs

27. App-E-Surv-Report-3-Acute-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-acute-pain.xlsx
    May 29, 2025 - and 1 year 1 week to >4 weeks A vs. … 2 weeks to <4 weeks ≥4 weeks A vs. … , p>0.05; 2.9 vs. 4.2 at 6 weeks, p>0.05 A vs. … , p=0.43; 77.9 (23.5) vs. 72.1(23.5) at 6 weeks, p=0.92 A vs. … , p=0.74; 56.3 (29.7) vs. 50.0 (25.0) at 6 weeks, p=0.17 A vs.

28. App-E-Surv-Report-2-Acute-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-acute-pain.xlsx
    May 29, 2025 - and 1 year 1 week to >4 weeks A vs. … 2 weeks to <4 weeks ≥4 weeks A vs. … , p>0.05; 2.9 vs. 4.2 at 6 weeks, p>0.05 A vs. … , p=0.43; 77.9 (23.5) vs. 72.1(23.5) at 6 weeks, p=0.92 A vs. … , p=0.74; 56.3 (29.7) vs. 50.0 (25.0) at 6 weeks, p=0.17 A vs.

29. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_executive.pdf
    September 01, 2011 - of gestation), very preterm (28 weeks to 31 weeks of gestation), preterm (32 weeks to 33 weeks of gestation … c. women between 32 weeks and 33 weeks of gestation (preterm)? … , < 32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birth weight, ratio of birth … , <32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy, bronchopulmonary dysplasia, significant … weeks, 95% CI range: 0.43–0.48 weeks, 0.92–0.97 weeks).13,15-19 Most participants in the cohort studies

30. Infectious Disease Including HIV/AIDS #09 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1506.pdf
    December 01, 2015 - from $97,000 to $103,000 for 12 weeks. … with HCV genotype 2, for 24 weeks for patients infected with genotype 3, and for 12 weeks with IFN … Eight weeks of Harvoni therapy was noninferior to 12 weeks of therapy.23 In the phase III ION-2, open-label … In patients treated for 12 weeks, 92% achieved SVR12; in patients treated for 24 weeks, 96% achieved … , or Sovaldi plus weight-based RBV for 24 weeks

31. Back-Pain-Imaging Clinician (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/back-pain-imaging_clinician.pdf
    April 01, 2016 - The study population consisted of patients who underwent lumbar spine imaging within 6 weeks of their … Controls did not have any spine imaging within 6 weeks of the index visit. … with activities, depression and anxiety, health- related quality of life, and falls in the past 3 weeks … Adjustments were made for the site in each analysis. »» Baseline measures were administered up to 3 weeks … with back pain without radiculopathy, there is no evi- dence that routine imaging within the first 6 weeks

32. Treatment of Depression in Children and Adolescents: A Systematic Review - Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/Evidence%20Summary_0_0.pdf
    April 01, 2020 - We present end- of-treatment data for all studies; these vary widely from weeks to months. … TAU/UC 12-16 weeks Depressive symptoms, clinician- reported Mean difference (CDRS): 7.11; … active control 12 weeks Response Risk difference (CGI of 2 or less and at least a 50% reduction … Escitalopram also improves functional status and response and remission at 24 weeks. … pharmacotherapy 8-28 weeks (continued) Remission from MDD Risk difference (combination vs.

33. Draft - Primary Hypofractionated Radiation Therapy for Localized Prostate Cancer: Appendix D2 Tables (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypofractionated-radiation-therapy-draft-appendix-d2.xlsx
    January 01, 2024 - The planning CT or MRI was done 2 weeks before start of radiotherapy...Hormonal therapy was given to … (≥28 days) or 57 Gy in 19 fractions in 3·8 weeks (≥27 days)…All treatment groups received IMRT. … (≥28 days) or 57 Gy in 19 fractions in 3·8 weeks (≥27 days)…All treatment groups received IMRT. … (≥28 days) or 57 Gy in 19 fractions in 3·8 weeks (≥27 days)…All treatment groups received IMRT. … The two arms were each finished in about 5 weeks (5.5 weeks for MHF), facilitating the comparison of

34. Evidence Summary CER 208 Treatment For Bipolar Disorder In Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-evidence-summary.pdf
    August 01, 2018 - placebo 5 RCT11, 16-19 (n=1199) 3 weeks Response Rate: Favors Olanzapine, OR 1.99 (95% CI 1.29, … placebo 4 RCT20-23 (n=1,007) 3 weeks Response Rate: Favors Quetiapine, OR 2.07 (95% CI 1.39, 3.09 … placebo 2 RCT25, 26 (n=584) 3 weeks Response Rate, YMRS, and CGI: Favors Risperidone (not pooled) … , 29, 30 (n=750) 3 weeks YMRS: No difference 3 RCTs18, 29, 30 (n=578) 3 weeks CGI: No difference … (n=453) 3 weeks Withdrawal (Overall, AE): No difference 1 IPD32 (n=453) 3 weeks Withdrawal (

35. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
    December 29, 2015 - , and 4 weeks, followed by 1 subcutaneous (SC) injection (75 mg or 150 mg) every 4 weeks;3 or secukinumab … 4 weeks, followed by one SC injection (75 or 150 mg) every 4 weeks. … , followed by 1 SC injection every 4 weeks. … ,42 or as 3 loading doses by IV infusion 10 mg/kg, at baseline, 2 weeks, and 4 weeks, followed by one … , and 4 weeks, followed by one SC injection (75 or 150 mg) every 4 weeks.

36. Evidence Summary Comparative Effectiveness Review No. 250: Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-other-plant-based-treatments-evidence-summary_0.pdf
    October 01, 2021 - placebo controlled) of patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks … to 8.67) 6.46 (4 to 8.1)c 5.38 (4.67 to 6.14) 6.28 (6.12 to 6.44) Study Duration 4 to 15 weeks … 8 to 12 weeks 4 to 47 weeks 4 weeks 4 weeks Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks … In the short term (4 weeks to <6 months), small magnitude improvements in pain severity and overall

37. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
    February 01, 2015 - Production Time: Less Than 4 Weeks Timeframe. … Production Time: 4 to 8 Weeks Timeframe. … used to make a decision at the end of those 2 weeks). … 12 weeks Yes N/A No N/A Yes No B1 Rapid review 3 days Yes N/A No No Yes No E2 Rapid review 4 weeks … One type relied on existing SRs. 1-2 weeks Two reports were conducted in 1 to 2 weeks.

38. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/gestational-diabetes-screening-diagnosis_research-protocol.pdf
    December 16, 2011 - A) After 24 weeks’ gestation? B) During the first trimester and up to 24 weeks’ gestation? …  Population: Pregnant women (≥24 weeks’ gestation and <24 weeks’ gestation) without known preexisting …  Population: Pregnant women (≥24 weeks’ gestation and <24 weeks’ gestation) without known preexisting …  Population: Pregnant women (≥24 weeks’ gestation and <24 weeks’ gestation) without known preexisting … Population We will include studies that examine pregnant women ≥24 weeks’ or <24 weeks’ gestation

39. Cer-250-Cannabis-2025-Surv-Rep-Update-Tables-E1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-tables-e1-4.xlsx
    January 01, 2025 - , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … CBD 5 mg, increased during weeks 1-4 to a max daily dose of 10 capsules per day (50 mg). … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

40. EHC Research Protocol (Amended): Treatments for Acute Episodic Migraine (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-treatments-research-amended-protocol.pdf
    January 09, 2020 - ; 2 weeks to 4 weeks? … ; 2 weeks to 4 weeks? … ; 2 weeks to 4 weeks? … ; 2 weeks to 4 weeks None 7 PICOTS Elements Inclusion Criteria Exclusion Criteria … ; 2 weeks to 4 weeks), patient demographics (e.g. age, race, ethnicity, gender, socioeconomic status